Johnson & Johnson (NYSE:JNJ) Stock Price Up 1.5% – Here’s Why

Johnson & Johnson (NYSE:JNJ) shares shot up 1.5% on Wednesday . The stock traded as high as $228.57 and last traded at $227.8640. 8,959,104 shares changed hands during trading, a decline of 5% from the average session volume of 9,387,904 shares. The stock had previously closed at $224.44.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 beat and strong 2026 guidance: J&J reported an EPS and revenue beat for Q4 and set 2026 sales guidance of $100–$101B and EPS guidance that exceeded consensus, signaling durable growth across Innovative Medicines and MedTech that offsets Stelara LOE. Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?
• Positive Sentiment: FDA approval expands oncology franchise: The FDA approved DARZALEX FASPRO in a D‑VRd quadruplet regimen for newly diagnosed, transplant‑ineligible multiple myeloma — a meaningful label expansion that strengthens J&J’s oncology revenue runway. DARZALEX FASPRO-based quadruplet regimen approved in the US
• Positive Sentiment: Analyst bullishness and price-target lifts: Firms including Guggenheim have raised outlooks/targets (example: PT moved toward $240) and coverage shows a bullish tilt after J&J’s results and guide, supporting further upside. Guggenheim Lifts Johnson & Johnson (JNJ) Outlook After Solid Q4 and 2026 Guide
• Positive Sentiment: Positive market technicals / options flow: Recent call-buying activity and strong short‑ and medium‑term performance (weekly/monthly gains) suggest bullish positioning by traders that can amplify upside. Johnson & Johnson Stock Forecast: Trending Bullish Among Analysts
• Neutral Sentiment: Corporate social/brand actions: J&J marked $100M of MedTech product donations since 2020 — positive for reputation and ESG but unlikely to move near‑term earnings. Johnson & Johnson Marks $100 Million of MedTech Products Donated
• Negative Sentiment: Policy and cost risks remain: Commentary and coverage note looming policy costs and potential reimbursement/regulatory pressures that could weigh on margins or growth in some markets, representing a medium‑term headwind to watch. JNJ Delivers Strong 2026 Guidance Even as Policy Costs Loom

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. Citigroup upped their target price on shares of Johnson & Johnson from $232.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a report on Friday, January 23rd. Loop Capital set a $220.00 target price on Johnson & Johnson in a report on Tuesday. The Goldman Sachs Group reaffirmed a “buy” rating and set a $250.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Sunday. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $230.36.

Johnson & Johnson Trading Up 1.5%

The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market capitalization of $548.99 billion, a P/E ratio of 20.62, a price-to-earnings-growth ratio of 2.15 and a beta of 0.34. The firm has a fifty day moving average price of $209.28 and a 200-day moving average price of $190.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting the consensus estimate of $2.46. The business had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.3%. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Institutional Trading of Johnson & Johnson

Several hedge funds have recently made changes to their positions in the company. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson during the third quarter valued at about $26,000. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson in the 3rd quarter worth approximately $28,000. Family CFO Inc bought a new position in Johnson & Johnson in the 4th quarter worth approximately $31,000. Finally, Semmax Financial Advisors Inc. grew its stake in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.